A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 115
- 试验地点
- 12
- 主要终点
- Part 2: Progression-Free Survival (PFS)
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to compare the efficacy between BAX69 in combination with 5-FU/LV for subjects with KRAS or NRAS mutated tumor (mt) or panitumumab, for subjects with KRAS and NRAS wild type tumor (wt) and standard of care (SoC) per investigator choice as third or fourth treatment line in subjects with progressive measurable metastatic colorectal cancer (mCRC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of a signed informed consent
- •Male and female subjects 18 years of age and older at the time of screening
- •Subjects who progressed after receiving at least 2, but no more than 3, prior SoC treatment lines
- •Anticipated life expectancy >3 months at the time of screening
- •Weight between 40 kg and 180 kg
- •Histologically or cytologically confirmed diagnosis of CRC
- •Metastatic CRC not amenable to surgical resection
- •Known KRAS and NRAS mutation status (if unknown status for either of these genes, and no archival tissues is available, a fresh tumor biopsy will be made)
- •At least 1 measurable lesion as defined by RECIST v1.1
- •ECOG PS of 0-2
- •Adequate hematological function, defined as:
- •Platelet count ≥ 100,000/μL
- •Prothrombin time and activated partial thromboplastin time (aPTT) < 1.5 times the upper limit of normal (ULN)
- •Absolute neutrophil count (ANC) ≥ 1,000/μL
- •Hemoglobin ≥ 9 g/dL, without the need for transfusion in the 2 weeks prior to screening
- •Adequate renal function, defined as serum creatinine ≤ 2.0 times ULN and creatinine clearance > 50 mL/min
- •Adequate liver function, defined as:
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
- •≤ 2.5 times ULN for subjects without liver metastases, or ≤ 5 times ULN in the presence of liver metastases
- •Bilirubin ≤ 2.0 times ULN, unless subject has known Gilbert's syndrome
- •Adequate venous access
- •For female subjects of childbearing potential, the subject presents with a negative serum pregnancy test at screening and agrees to employ 2 forms of adequate birth control measures, including at least 1 barrier method (eg, diaphragm with spermicidal jelly or foam, or [for male partner] condom) throughout the course of the study and for at least 90 days after the last administration of BAX
- •Other acceptable contraceptive measures include birth control pills/patches or intrauterine devices
- •For male subjects, the subject must agree to use adequate contraceptive measures including at least 1 barrier method (eg, condom with spermicidal jelly or foam and [for the female partner] diaphragm with spermicidal jelly or foam, birth control pills/patches, or intrauterine device) and abstain from sperm donation throughout the course of the study and for at least 90 days after the last administration of BAX69
- •Subject is willing and able to comply with the requirements of the protocol.
排除标准
- •Known central nervous system metastases
- •Prior malignancy(s) within the past 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin, locally advanced prostate cancer, ductal carcinoma in situ of breast, in situ cervical carcinoma and superficial bladder cancer
- •Prior treatment with panitumumab for subjects with KRAS and NRAS wt tumor
- •Residual AE from previous treatment > Grade 1
- •Prior intolerance to fluoropyrimidine for subjects with KRAS or NRAS mut tumor
- •Myocardial infarction within 6 months prior to C1D1, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication; and/or the subject is at risk for polymorphic ventricular tachycardia (eg, hypokalemia, family history or long QT syndrome)
- •Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg confirmed upon repeated measures
- •LVEF < 40% as determined by echocardiogram performed at screening or within 90 days prior to C1D1
- •QT/QTc interval > 450 msec, as determined by screening ECG performed no earlier than 1 week before C1D1
- •Prior anti-tumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular targeted therapy, retinoid therapy or hormonal therapy) within 4 weeks prior to C1D
- •Major surgery within 4 weeks prior to C1D1
- •Active joint inflammation or history of inflammatory arthritis or other immune disorder involving joints
- •Active infection involving IV antibiotics within 2 weeks prior to C1D1
- •Known history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis
- •Known history of human immunodeficiency virus (HIV) type 1/2 or other immunodeficiency disease
- •Subject has received a live vaccine within 4 weeks prior to C1D1
- •Known hypersensitivity to any component of recombinant protein production by CHO cells
- •Exposure to an investigational product or investigational device in another clinical study within 4 weeks prior to C1D1, or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study
- •Subject is nursing or intends to begin nursing during the course of the study
- •Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests, ECG), that in medical judgment of the investigator may impede the subject's participation in the study, pose increased risk to the subject, and/or confound the results of the study
- •Subject is a family member or employee of the investigator
研究组 & 干预措施
Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)
Subjects stratified according to their mutation status.
干预措施: BAX69 + infusional 5-FU/LV (Biological)
Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)
Subjects stratified according to their mutation status.
干预措施: BAX69 + panitumumab (Biological)
Part 2: Subjects with KRAS or NRAS mutated
Subjects stratified according to their mutation status.
干预措施: BAX69 + 5-FU/LV (Biological)
Part 2: Subjects with KRAS and NRAS wt tumor
Subjects stratified according to their mutation status.
干预措施: BAX69 + panitumumab (Biological)
Part 2: Standard of Care- Subjects with KRAS or NRAS mutated
Subjects stratified according to their mutation status.
干预措施: Standard of Care (Biological)
Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor
Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
干预措施: Standard of Care (Biological)
结局指标
主要结局
Part 2: Progression-Free Survival (PFS)
时间窗: From start of the study up to safety follow-up visit occurred (30 [-/+7]) days after the last dose of study treatment or until disease progression
PFS was defined as time between treatment initiation and tumor progression (per Response Evaluation Criteria in Solid Tumors \[RECIST\] v1.1 criteria) or death from any cause, with censoring of participants who were lost to follow-up or withdrew consent.
Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT)
时间窗: From start of study treatment up to 28 days
DLT was defined as any drug-related treatment-emergent adverse event (TEAE) (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v4.03) that occurs during the first 28 days after treatment start and that meets any of the following criteria: i) Any \>= Grade 3 non-hematologic toxicity (excluding: mucositis/stomatitis of Grade 3; diarrhea of \<3 days duration; nausea and vomiting \<3 days duration; fatigue of \<7 days duration; alopecia; single laboratory value out of the normal range that has no clinical significance and that resolves to \<= Grade 2 with adequate measures within 7 days) ii) Any Grade 4 hematologic toxicity (excluding: grade 4 neutropenia lasting for \<= 5 days; isolated grade 4 lymphocytopenia) iii) Grade 3 febrile neutropenia iv) Grade 3 thrombocytopenia associated with bleeding v) Any life-threatening complication or abnormality not covered in NCI CTCAEv4.03.
次要结局
- Number of Participants With Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs)(From start of study drug administration up to EOT (approximately 21 Months))
- Number of Participants With Occurrence of Binding and/or Neutralizing Anti-imalumab Antibodies(From start of study drug administration up to end of treatment (EOT) (approximately 21 Months))
- Number of Participants With Response Evaluation According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1(Day 28 of Cycle 2 followed by every 2 Cycles of 28 day Cycles: Day 56, Day 112, Day 168 and Day 224)
- Overall Survival(From start of study drug administration up to EOT (approximately 21 Months))
- Number of Participants With Incidence of Infusion Reactions After Imalumab Administration(From start of study drug administration up to EOT (approximately 21 Months))
- Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)(Baseline, 21 Months (EOT) up to follow-up)